Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 19/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16141298 | 1.00 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16107835 | 1.00 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16141316 | 1.00 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14934655 | 1.00 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14934452 | 1.00 | SCN9A (0.66) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL17797331 | 0.96 | SCN9A (0.60) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL17797330 | 0.96 | SCN9A (0.60) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16141382 | 0.96 | SCN9A (0.60) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL14934635 | 0.96 | SCN9A (0.60) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A | |
| SCHEMBL16107890 | 0.95 | SCN9A (0.59) | SCN9ACYP3A4CYP2D6CYP2C9SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9630929-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2017-04-25 | — | — | US | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| EP-2773637-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2016-06-08 | — | — | EP | disclosed |
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2014-10-02 | — | — | US | disclosed |
| WO-2013064983-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296245-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV1, TRPA1, TRPV3 | SCN9A 39/4885CYP3A4 681/4885CYP2D6 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.